Kardaś I, Seitz G, Limon J, Niezabitowski A, Ryś J, Theisinger B, Welter C, Blin N
Department of Genetics & Biology, Medical Academy, Gdansk, Poland.
Cancer. 1993 Sep 1;72(5):1652-6. doi: 10.1002/1097-0142(19930901)72:5<1652::aid-cncr2820720526>3.0.co;2-4.
The estrogen-inducible pS2 gene, originally isolated from a breast cancer cell line, is correlated with hormone-dependent female breast tumors and its expression is associated with longer overall and disease-free survival.
The authors have investigated 38 samples of carcinomas of the male breast for pS2 expression by using a monoclonal antibody. The immunostaining was compared with clinical data, in particular, to the progesterone receptor status, to assess a possible prognostic value of this parameter.
Although most cases (27 of 38) were immunopositive (i.e., above the 5th percentile of immunoreactive cells), no correlation with tumor grade and survival was notable.
Therefore, on the contrary to the situation in female breast cancer, pS2 activity failed to constitute a new prognostic parameter in male breast carcinomas.
雌激素诱导的pS2基因最初从乳腺癌细胞系中分离出来，与激素依赖性女性乳腺肿瘤相关，其表达与更长的总生存期和无病生存期相关。
作者使用单克隆抗体研究了38例男性乳腺癌样本中的pS2表达。将免疫染色结果与临床数据进行比较，尤其是与孕激素受体状态进行比较，以评估该参数可能的预后价值。
尽管大多数病例（38例中的27例）免疫呈阳性（即免疫反应性细胞高于第5百分位数），但与肿瘤分级和生存期无明显相关性。
因此，与女性乳腺癌的情况相反，pS2活性未能成为男性乳腺癌新的预后参数。
